Cargando…

Therapeutic Drug Monitoring of Ganciclovir: Where Are We?

Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Märtson, Anne-Grete, Edwina, Angela E., Kim, Hannah Yejin, Knoester, Marjolein, Touw, Daan J., Sturkenboom, Marieke G. G., Alffenaar, Jan-Willem C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Drug Monitoring 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746890/ https://www.ncbi.nlm.nih.gov/pubmed/34610621 http://dx.doi.org/10.1097/FTD.0000000000000925

Ejemplares similares

Ganciclovir Therapeutic Drug Monitoring: A Case Series
por: Märtson, Anne-Grete, et al.
Publicado: (2019)

Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?
por: Martson, Anne-Grete, et al.
Publicado: (2019)

Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication
por: Marfil, Sjanene, et al.
Publicado: (2023)

Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study
por: Grit, Geeske F., et al.
Publicado: (2022)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections
por: Alffenaar, Jan-Willem, et al.
Publicado: (2021)

Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.
por: Kim, Hannah Yejin, et al.
Publicado: (2020)

Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs” [Clin. Mass Spectrom. 14(Part A) (2019) 34–45]
por: Kuhlin, Johanna, et al.
Publicado: (2022)

In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin
por: van der Mast, Jackelien E., et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Precision Therapy for Invasive Fungal Diseases
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children
por: Stockmann, Chris, et al.
Publicado: (2016)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
por: Sturkenboom, Marieke G. G., et al.
Publicado: (2021)

Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study
por: Märtson, Anne-Grete, et al.
Publicado: (2023)

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis
por: Saktiawati, Antonia Morita I., et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article
por: Touw, Daan J., et al.
Publicado: (2022)

Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
por: Taveira-DaSilva, Angelo M, et al.
Publicado: (2009)

Therapeutic Drug Monitoring of Antiseizure Medications Using Volumetric Absorptive Microsampling: Where Are We?
por: D’Urso, Annachiara, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
por: Choong, Eva, et al.
Publicado: (2022)

Does Chemotherapy-Induced Gastrointestinal Mucositis Affect the Bioavailability and Efficacy of Anti-Infective Drugs?
por: da Silva Ferreira, Ana Rita, et al.
Publicado: (2021)

NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir
por: Nishii, Rina, et al.
Publicado: (2021)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

The need for area under the curve measurements in the field of ganciclovir therapeutic drug monitoring in children: a case report
por: Duval, Xavier, et al.
Publicado: (2021)

A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots
por: Pigliasco, Federica, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Ganciclovir in Cytomegalovirus-Infected Patients With Solid Organ Transplants and Its Correlation to Efficacy and Toxicity
por: van der Wekken-Pas, Lena C., et al.
Publicado: (2023)

Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
por: Ojha, Probir Kumar, et al.
Publicado: (2020)

A desensitization protocol to ganciclovir
por: Cernadas, Josefina Rodrigues, et al.
Publicado: (2014)

Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
por: van den Elsen, Simone HJ, et al.
Publicado: (2020)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Therapeutic Intervention in Motor Disorders at Young and Old Age: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2001)

Animal Models for COVID-19 Therapeutic Development: Where We Are and Where We Need to Go
por: Zhao, Sihai, et al.
Publicado: (2022)

Are we ready for therapeutic drug monitoring of biologic therapeutics?
por: Krieckaert, Charlotte LM, et al.
Publicado: (2011)

Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report
por: Sunada, Mariko, et al.
Publicado: (2016)

Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Alopecia Areata in Latin America: Where are We and Where are We Going?
por: Velásquez-Lopera, Margarita M., et al.
Publicado: (2022)

Hepatitis C Vaccination: Where We Are and Where We Need to Be
por: Manne, Vignan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4fru03d0np204umhsh7pd3s7ju